MyFinsight
Home
Blog
About
Cash and cash
equivalents
$482,575K
(273.72%↑ Y/Y)
Accounts receivable, net
$401,565K
(73.45%↑ Y/Y)
Inventory
$147,973K
(-4.66%↓ Y/Y)
Short-term investment
securities
$69,673K
(-43.24%↓ Y/Y)
Other current assets
$43,901K
(73.02%↑ Y/Y)
Total current assets
$1,145,687K
(72.55%↑ Y/Y)
Deferred tax assets
$343,428K
Non-current inventories
$75,486K
Long-term investment
securities
$64,368K
(125.14%↑ Y/Y)
Right of use assets
$7,085K
(5.46%↑ Y/Y)
Other noncurrent
assets
$2,211K
(9.08%↑ Y/Y)
Restricted cash
$1,364K
(3.65%↑ Y/Y)
Total assets
$1,639,629K
(133.36%↑ Y/Y)
Total liabilities and
stockholders equity
$1,639,629K
(133.36%↑ Y/Y)
Total liabilities
$1,035,546K
(142.98%↑ Y/Y)
Total stockholders
equity
$604,083K
(118.53%↑ Y/Y)
Accumulated deficit
-$1,054,457K
(29.51%↑ Y/Y)
Treasury stock, at cost,
6,871,546 and 3,543,643...
$200,226K
(810.45%↑ Y/Y)
Loan payable
non-current
$745,387K
(204.19%↑ Y/Y)
Total current
liabilities
$268,493K
(56.20%↑ Y/Y)
Deferred revenue,
non-current portion
$14,525K
(771.33%↑ Y/Y)
Lease liability
non-current
$7,141K
(-5.89%↓ Y/Y)
Additional paid-in capital
$1,858,606K
(3.59%↑ Y/Y)
Common stock, 0.001 par
value per share...
$160K
(0.63%↑ Y/Y)
Accounts payable and
accrued expenses
$213,693K
(59.45%↑ Y/Y)
Accrued compensation
$35,205K
(231.81%↑ Y/Y)
Deferred revenue -
current portion
$16,825K
(-29.63%↓ Y/Y)
Lease liability
current portion
$1,913K
(75.34%↑ Y/Y)
Other current
liabilities
$857K
(-62.01%↓ Y/Y)
Back
Back
Balance Sheet
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
source: myfinsight.com